Jun 09, 2023 / 02:00PM GMT
Unidentified_Participant
Welcome, everyone. This is [Yao], equity research associate at Jefferies. It is my great pleasure to welcome our guests, Linda Rubinstein, CFO of Adverum Biotechnologies, will give us a presentation today. Please take away.
Linda Rubinstein - Adverum Biotechnologies, Inc. - CFO
Thank you, and thank you to Jefferies for having Adverum to present at the conference. I'm delighted to tell you about Adverum, we're a gene therapy company focusing on highly prevalent ocular diseases. Our lead program, Ixo-vec is in Phase 2 for wet AMD, and we'll be presenting data on a trial starting in Q3 of this year.
Importantly, we have unparalleled data based on our OPTIC trial, including data showing that our drug is effective past three years, and we are looking forward to replicating that data in our new trial. We are well funded with cash into 2025.
Though anti-VEGF market for wet AMD is very large, global revenues are about $13 billion, Eylea is the monster in there with $10 billion in revenues, of which two-thirds are in the US and one
Adverum Biotechnologies Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers